Novel therapeutic targets in viral myocarditis

Future Virology

Volumn 3, Issue 4, 2008, Pages 373-381

  Miyamoto, Shelley D ^a   DeBiasi, Roberta L ^b   Long, Carlin S ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cardiac remodeling; Immune system; Myocarditis; Treatment; Viral infection

Indexed keywords

5 [5 [2,6 DICHLORO 4 (4,5 DIHYDRO 2 OXAZOLYL)PHENOXY]PENTYL] 3 METHYLISOXAZOLE; ANGIOTENSIN II ANTAGONIST; ANTIVIRUS AGENT; BETA INTERFERON; CANDESARTAN; CASPASE INHIBITOR; FINGOLIMOD; I KAPPA B; IMMUNOGLOBULIN; INTERFERON; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; MURONOMAB CD3; PIMOBENDAN; PLECONARIL; PYCNOGENOL; STEROID; SUN C8079; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; APOPTOSIS; AUTOIMMUNITY; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CYTOKINE RELEASE; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG TARGETING; EARLY DIAGNOSIS; HEART FAILURE; HEART VENTRICLE REMODELING; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS MYOCARDITIS; VIRUS REPLICATION; VIRUS VIRULENCE;

EID: 55849092548     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.3.4.373     Document Type: Review

References (77)

1. Aretz HT, Billingham ME, Edwards WD et al.: Myocarditis: a histopathologic definition and classification. Am. J. Cardiovasc. Pathol. 1(1), 3-14 (1987).
2. Kawai C: From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 99(8), 1091-1100 (1999).
3. Feldman AM, McNamara D: Myocarditis. N. Engl. J. Med. 343(19), 1388-1398 (2000).
4. Liu PP, Mason JW: Advances in the understanding of myocarditis. Circulation 104(9), 1076-1082 (2001).
5. Liu Z, Yuan J, Yanagawa B, Qiu D, McManus BM, Yang D: Coxsackievirus-induced myocarditis: new trends in treatment. Expert Rev. Anti Infect. Ther. 3(4), 641-650 (2005).
6. Abzug MJ: Presentation, diagnosis, and management of enterovirus infections in neonates. Paediatr. Drugs 6(1), 1-10 (2004).
7. Goodfellow IG, Evans DJ, Blom AM et al.: Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors, J. Virol. 79(18), 12016-12024 (2005).
8. Pauschinger M, Bowles NE, Fuentes-Garcia FJ et al.: Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation 99(10), 1348-1354 (1999).
9. Ryder NS: Discontinued drugs in 2006: anti-infectives. Expert Opin. Investig. Drugs 16(12), 1867-1878 (2007).
10. + B lymphocytes. Apoptosis 12(9), 1633-1643 (2007).
11. Martin U, Jarasch N, Nestler M et al.: Antiviral effects of pan-caspase inhibitors on the replication of coxsackievirus B3. Apoptsis 12(3), 525-533 (2007).
12. DeBiasi RL, Edelstein CL, Sherry B, Tyler KL: Calpain inhibition protects against virus-induced apoptotic myocardial injury. J. Virol. 75(1), 351-361 (2001).
13. DeBiasi RL, Robinson BA, Sherry B et al.: Caspase inhibition protects against reovirus-induced myocardial injury in vitro and in vivo. J Virol. 78(20), 11040-11050 (2004).
14. Khoynezhad A, Jalali Z, Tortolani AJ: A synopsis of research in cardiac apoptosis and its application to congestive heart failure. Tex. Heart Inst. J. 34(3), 352-359 (2007).
15. Saraste A, Pulkki K: Morphologic and biochemical hallmarks of apoptosis. Cardiovasc. Res. 45(3), 528-537 (2000).
16. Marshall WL, Yim C, Gustafson E et al.: Epstein-Barr virus encodes a novel homolog of the Bcl-2 oncogene that inhibits apoptosis and associates with Bax and Bak. J. Virol. 73(6), 5181-5185 (1999).
17. Saraste A, Arola A, Vuorinen T et al.: Cardiomyocyte apoptosis in experimental coxsackievirus B3 myocarditis. Cardiovasc. Pathol. 12(5), 255-262 (2003).
18. Debiasi RL, Squier MK, Pike B et al.: Reovirus-induced apoptosis is preceded by increased cellular calpain activity and is blocked by calpain inbitors. J. Virol. 73(1), 695-701 (1999).
19. Clarke P, Richardson-Burns SM, DeBiasi RL, Tyler KL: Mechanisms of apoptosis during reovirus infection. Curr. Top. Microbiol. Immunol. 289, 1-24 (2005).
20. Sherry B, Schoen FJ, Wenske E, Fields BN: Derivation and characterization of an efficiently myocarditic reovirus variant. J. Virol. 63(11), 4840-4849 (1989).
21. Sherry B, Li XY, Tyler KL, Cullen JM, Virgin HWT: Lymphocytes protect against and are not required for reovirus-induced myocarditis. J. Virol. 67(10), 6119-6124 (1993).
22. Huber S, Dohrman A. Sartini D, Budd RC: Reduced myocarditis following coxsackievirus infection in cellular FLICE inhibitory protein: long form-transgenic mice. Immunology 119(4), 541-550 (2006).
23. Kyto V, Saraste A, Saukko P et al.: Apoptotic cardiomyocyte death in fatal myocarditis. Am. J. Cardiol. 94(6), 746-750 (2004).
24. Smith RM, Lecour S, Sack MN: Innate immunity and cardiac preconditioning: a putative intrinsic cardioprotective program. Cardiovasc. Res. 55(3), 474-482 (2002).
25. Kanzler H, Barrat FJ, Hessel EM, Coffman RL: Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13(5), 552-559 (2007).
26. Hardarson HS, Baker JS, Yang Z et al.: Toll-like receptor 3 is an essential component of the innate stress response in virus-induced cardiac injury. Am. J. Physiol. Heart Circ. Physiol. 292(1). H251-H258 (2007).
27. Godeny EK, Gauntt CJ: Murine natural killer cells limit coxsackievirus B3 replication. J. Immunol. 139(3), 913-918 (1987).
28. Mann DL: Interleukin-6 and viral myocarditis: the Yin-Yang of cardiac innate immune responses. J. Mol. Cell. Cardiol. 33(9), 1551-1553 (2001).
29. Wada H, Saito K, Kanda T et al.: Tumor necrosis factor-α (TNF-α) plays a protective role in acute viral myocarditis in mice: a study using mice lacking TNF-α. Circulation 103(5), 743-749 (2001).
30. Satoh M, Nakamura M, Akatsu T et al.: Expression of Toll-like receptor 4 is associated with enteroviral replication in human myocarditis. Clin. Sci. 104(6), 577-584 (2003).
31. Satoh M, Akatsu T, Ishikawa Y, Minami Y, Takahashi Y, Nakamura M: Association between toll-like receptor 8 expression and adverse clinical outcomes in patients with enterovirus-associated dilated cardiomyopathy. Am. Heart J. 154(3), 581-588 (2007).
32. Calabrese F, Carturan E, Chimenti C et al.: Overexpression of tumor necrosis factor (TNF)α and TNFα receptor I in human viral myocarditis: clinicopathologic correlations. Mod. Pathol. 17(9), 1108-1118 (2004).
33. Matsumori A, Nunokawa Y, Yamaki A et al.: Suppression of cytokines and nitric oxide production, and protection against lethal endotoxemia and viral myocarditis by a new NF-κB inhibitor. Eur. J. Heart Fail. 6(2), 137-144 (2004).
34. Iwasaki A, Matsumori A, Yamada T et al.: Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. J. Am. Coll. Cardiol. 33(5), 1400-1407 (1999).
35. Hosseini S, Pishnamazi S, Sadrzadeh SM, Farid F, Farid R, Watson RR: Pycnogenol® in the management of asthma. J. Med. Food 4(4), 201-209 (2001).
36. Matsumori A, Higuchi H, Shimada M: French maritime pine bark extract inhibits viral replication and prevents development of viral myocarditis. J. Card. Fail. 13(9), 785-791 (2007).
37. Yuan Z, Nimata M, Okabe TA et al.: Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure. Am. J. Physiol. Heart Circ. Physiol. 289(3). H1147-H1152 (2005).
38. Yu F, Chen R, Takahashi T et al.: Candesartan improves myocardial damage in obese mice with viral myocarditis and induces cardiac adiponectin. Int. J. Cardiol. (2007).
39. Saegusa S, Fei Y, Takahashi T et al.: Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expression. Cardiovasc. Drugs Ther. 21(3), 155-160 (2007).
40. Stewart MJ, Smoak K, Bium MA, Sherry B: Basal and reovirus-induced β interferon (IFN-β) and IFN-β-stimulated gene expression are cell type specific in the cardiac protective response. J. Virol. 79(5), 2979-2987 (2005).
41. Wang YX, da Cunha V, Vincelette J et al.: Antiviral and myocyte protective effects of murine interferon-β and -α2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice. Am. J. Physiol. Heart Circ. Physiol. 293(1), H69-H76 (2007).
42. Jarasch N, Martin U, Kamphausen E, Zell R, Wutzler P, Henke A: Interferon-γ-induced activation of nitric oxide-mediated antiviral activity of macrophages caused by a recombinant coxsackievirus B3. Viral Immunol. 18(2), 355-364 (2005).
43. Lenzo JC, Mansfield JP, Sivamoorthy S, Cull VS, James CM: Cytokine expression in murine cytomegalovirus-induced myocarditis: modulation with interferon-α therapy. Cell. Immunol. 223(1), 77-86 (2003).
44. Fairweather D, Frisancho-Kiss S, Yusung SA et al.: IL-12 protects against coxsackievirus B3-induced myocarditis by increasing IFN-γ and macrophage and neutrophil populations in the heart. J. Immunol. 174(1), 261-269 (2005).
45. Afanasyeva M, Wang Y, Kaya Z et al.: Interleukin- 12 receptor/ STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-γ-independent pathway. Circulation 104(25), 3145-3151 (2001).
46. Padalko E, Nuyens D, De Palma A et al.: The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Antimicrob. Agents Chemother. 48(1), 267-274 (2004).
47. Kuhl U, Pauschinger M, Schwimmbeck PL et al.: Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107(22), 2793-2798 (2003).
48. McCarthy RE 3rd, Boehmer JP, Hruban RH et al.: Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N. Engl. J. Med. 342(10), 690-695 (2000).
49. Mason JW, O'Connell JB, Herskowitz A et al.: A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl. J. Med. 333(5), 269-275 (1995).
50. Robinson J, Hartling L, Vandermeer B, Crumley E, Klassen TP: Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane Database Syst. Rev. (1), CD004370 (2005).
51. Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A: Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 107(6), 857-863 (2003).
52. Cooper LT, Baughman KL, Feldman AM et al.: The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J. Am. Coll. Cardiol. 50(19), 1914-1931 (2007).
53. McNamara DM, Holubkov R, Starling RC et al.: Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 103(18). 2254-2259 (2001).
54. Chen H, Liu J, Yang M: Corticosteroids for viral myocarditis. Cochrane Database Syst. Rev. (4), CD004471 (2006).
55. Frisancho-Kiss S, Davis SE, Nyland JF et al.: Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J. Immunol. 178(11), 6710-6714 (2007).
56. Perens G, Levi DS, Alejos JC, Wetzel GT: Muronomab-CD3 for pediatric acute myocarditis. Pediatr. Cardiol. 28(1), 21-26 (2007).
57. Kamiyoshi Y, Takahashi M, Yokoseki O et al.: Mycophenolate mofetil prevents the development of experimental autoimmune myocarditis. J. Mol. Cell. Cardiol, 39(3). 467-477 (2005).
58. Maeda K, Shioi T, Kosugi R et al.: Rapamycin ameliorates experimental autoimmune myocarditis. Int. Heart J. 46(3), 513-530 (2005).
59. Miyamoto T, Matsumori A, Hwang MW, Nishio R, Ito H, Sasayama S: Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis. J. Am. Coll. Cardiol. 37(6), 1713-1718 (2001).
60. Yuan Z, Liu Y, Liu Y et al.: Cardioprotective effects of peroxisome proliferator activated receptor-γ activators on acute myocarditis: anti-inflammatory actions associated with nuclear factor κB blockade. Heart 91(9), 1203-1208 (2005).
61. Padalko E, Verbeken E, Matthys P, Aerts JL, De Clercq E, Neyts J: Mycophenolate mofetil inhibits the development of coxsackie B3-virus-induced myocarditis in mice. BMC Microbiol. 3, 25 (2003).
62. Caforio AL, Tona F, Bottaro S et al.: Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity 41(1), 35-45 (2008).
63. Fairweather D, Kaya Z, Shellam GR, Lawson CM, Rose NR: From infection to autoimmunity. J. Autoimmun. 16(3), 175-186 (2001).
64. Schimke I, Muller J, Priem F et al. Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption. J. Am. Coll. Cardiol. 38(1), 178-183 (2001).
65. Dorffel WV, Wallukat G, Baumann G, Felix SB: Immunoadsorption in dilated cardiomyopathy. Ther. Apher. 4(3), 235-238 (2000).
66. Muller J, Wallukat G, Dandel M et al.: Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 101(4), 385-391 (2000).
67. Gullestad L, Aass H, Fjeld JG et al.: Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103(2), 220-225 (2001).
68. Felix SB, Staudt A: Nonspecific immunoadsorption in patients with dilated cardiomyopathy: mechanisms and clinical effects. Int. J. Cardiol. 112(1), 30-33 (2006).
69. Mahrholdt H, Wagner A, Deluigi CC et al..: Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 114(15), 1581-1590 (2006).
70. Figulla HR: Transformation of myocarditis and inflammatory cardiomyopathy to idiopathic dilated cardiomyopathy: facts and fiction. Med. Microbiol. Immunol. 193(2-3), 61-64 (2004).
71. Cheung C, Luo H, Yanagawa B et al.: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in coxsackievirus-induced myocarditis. Cardiovasc. Pathol. 15(2), 63-74 (2006).
72. Heymans S, Pauschinger M, De Palma A et al..: Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation 114(6), 565-573 (2006).
73. Cheung C, Marchant D, Walker EK et al.: Ablation of matrix metalloproteinase-9 increases severity of viral myocarditis in mice. Circulation 117 (12), 1574-1582 (2008).
74. Crocker SJ, Frausto RF, Whitmire JK, Benning N, Milner R, Whitton JL: Amelioration of coxsackievinss B3-mediated myocarditis by inhibition of tissue inhibitors of matrix metalloproteinase-1. Am. J. Pathol. 171(6), 1762-1773 (2007).
75. Li J, Leschka S, Rutschow S et al.: Immunomodulation by interleukin-4 suppresses matrix metalloproteinases and improves cardiac function in murine myocarditis. Eur. J. Pharmacol. 554(1), 60-68 (2007).
76. Yuan J, Stein DA, Lim T et al.: Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site. J. Virol. 80(23), 11510-11519 (2006).
77. Yuan J, Cheung PK, Zhang HM, Chau D, Yang D: Inhibition of coxsackievirus B3 replication by small interfering RNAs requires perfect sequence match in the central region of the viral positive strand. J. Virol. 79(4). 2151-2159 (2005).